The Indian drug industry, which has proven its strengths in manufacturing cheap generic or off-patent medicines for the global market, may soon find a similar generic opportunity in the molecular diagnostic segment. This is after the patent protection on molecular diagnostics based on PCR (polymerase chain reaction) platform expired globally.